Thermo’s Bold Bet on LIMS On Demand



By John Russell

May 18, 2010 | The Russell Transcript | For several years, the LIMS market (roughly $400 million worldwide) has been stuck in neutral. Most labs forego the use of commercial LIMS for various reasons—high cost, year-long deployment efforts, inflexibility, etc. But that’s all about to change, says Kim Shah, Thermo Fisher Scientific’s director of marketing, informatics.

Yes, Thermo, the giant instrument manufacturer whose supersized LIMS offerings are often portrayed as the archetype for big companies with far-flung operations, big IT staffs, and big budgets. The operative word is BIG. No longer, says Shah. In February, Thermo rolled out its LIMS-on-demand initiative in which the company will deliver its powerful LIMS using a software-as-a-service (SaaS) model. Thermo’s introductory offering is designed to lower the barrier to entry. The target market extends down to very small labs with just a few workers.

The life science market has finally accepted SaaS, says Shah. He points to efforts by Sciformatix, a young company with a hosted LIMS offering, and GenoLogics’ web-based collaboration tool (LabLink) as demonstrating market acceptance and demand. The SaaS model is the way of the future for many applications, he insists, and the client server world with its blizzard of license fees and support requirements will diminish. Think salesforce.com, Shah says, the popular web-based customer relationship management tool. “Some of these things are just laws of nature. There’s no reason why this industry or this application area should be any different.” It is clear that the recent recession and industry-specific pressures have inclined all of biopharma to externalize costs where possible.

Rather than rewrite its existing LIMS code, Thermo purchased technology to put a web-enabling “wrapper” around the existing product. It worked with customers testing the product in a variety of configurations—browser-based, but server inside the user company, browser-based but with the server outside the user’s firewall, etc.

The new offering will deliver all the advantages of a full-feature LIMS in a highly usable way. Reaching customers through a hosted log-on system essentially creates a new marketing channel to interact with customers. “Each time [the lab manager goes online, there could be a message waiting for them about a new method development or a new SOP or a new government ruling,” he says.

LIMS Evolution

Regulatory compliance was a big driver through LIMS’ first decade, Shah says. Most LIMS were used to manage paper and to “automate the process of taking data directly from an instrument into a piece of software. These steps were important in reducing errors, providing audit trails, and helping users to reach and maintain GLP practice.”

Globalization and the rise of the internet drove LIMS expansion (use and functionality) in the second decade. Companies began operating in multiple locations and started diversifying and outsourcing much of their value chain. The issue became how to harmonize those processes, so LIMS became valuable in creating standards for processes and methods.

In the third decade, companies started to look at investments already made in their laboratories—“instruments, laptops, software, and not just LIMS software. They are looking at ERP software, document management software, ELNs, and depending on the industry, even MES (manufacturing execution systems) systems.”

Looking at the new LIMS-on-Demand offering, Shah says it is very practical for a new user to get up and running in six months. Moreover, given a hosted LIMS option, he expects small labs will follow the same adoption curve as big users, evolving to make use of more sophisticated functionality. One key market segment is small labs with 3-5 scientists. “They will … say they are going to drive this lab into the 21st century by adopting this technology. In terms of usage, I think they will clearly have not a large volume of samples necessarily but there will be a time criticality in what they are doing.” Among the beta users is at least one big pharma and the University of Miami. The on-demand solution won’t work for everyone, concedes Shah. Customization requirements are problematic. “We can configure but can’t customize,” he says.

ThermoFisher is fond of saying its works with 350,000 labs, the bulk of which are buying consumables. Thermo Informatics works with something closer to 15,000 labs. That leaves a huge upside for the LIMS-on-Demand product. Customer expansion and effective use of the “new distribution channel” are early goals. Shah hopes to get 30-50 new customers by early 2011 and 100 the following year. It will be interesting to see if hosted LIMS offerings do indeed repeat a salesforce.com like success. 


This article also appeared in the May-June 2010 issue of Bio-IT World Magazine. Subscriptions are free for qualifying individuals. Apply today.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .